Science News
from research organizations

New Therapeutic Option For Human Hepatocyte Cancer

Date:
September 23, 2008
Source:
World Journal of Gastroenterology
Summary:
A group from Germany found that using H-1 parvovirus infection and chemotherapeutic treatment can enhance the cytotoxic effect of anti-cancer agents. Furthermore H-1 PV induces the expression of tumor suppressors such as p53 or promyelocytic leukemia protein, thus increased the suscebtibility to cell death in H-1 PV-infected tumor cells.
Share:
       
FULL STORY

A group from Germany found that using H-1 parvovirus infection and chemotherapeutic treatment can enhance the cytotoxic effect of anti-cancer agents. Furthermore H-1 PV induces the expression of tumor suppressors such as p53 or promyelocytic leukemia protein, thus increased the suscebtibility to cell death in H-1 PV-infected tumor cells.

p53-impaired tumors may be particularly suitable to parvovirus H-1-induced therapy. Although the p53 deficiency in tumors may induce resistance to chemotherapeutic agents, this will not affect the tumor cell susceptibility to H-1 PV-induced oncolytic infections. The parvovirus H-1 may also overcome other tumor resistance mechanisms developed in these tumor entities. So H-1 PV is a suitable agent to circumvent the resistance of p53-negative human hepatocellular carcinoma (HCC) cells to genotoxic agents, and enhances the apoptotic process which is dependent on functional PML. Thus, H-1 PV may be considered as therapeutic options for HCC, especially for p53-negative tumors.

The research team led by Prof. Markus Moehler from First Department of Internal Medicine of Johannes Gutenberg University of Mainz evaluated the synergistic targeting and killing of human HCC cells lacking p53 by the oncolytic autonomous PV H-1 with chemotherapeutic agents. This was published on 28 June 2008, in the World Journal of Gastroenterology.

Their result shows that parvovirus H-1 PV triggers an apoptotic type of death in human HCC cells, and that p53 is dispensable for this process. In contrast, PML, which is induced by H-1 PV infection, helps the parvovirus to kill the carcinoma cells, irrespective of their p53 status. Given the known dependence of apoptosis induction by radio-chemotherapeutic agents on the p53 status of target cells, parvoviruses appear to be suitable adjuvants to eliminate tumor cell populations with resistance against these agents by means of combined treatments. Parvovirus H-1 will be a new option for patients with human HCC and clinical phase I-II trials with these oncolytic gene therapy vectors should be done in the near future.

Many viruses are known to be pathogenic and increase carcinogenesis. In the contrary, the autonomous parvoviruses destroy tumors, activate the immune system and may thus even be good for the health of men.


Story Source:

The above post is reprinted from materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sieben M, Herzer K, Zeidler M, Heinrichs V, Leuchs B, Schuler M, Cornelis JJ, Galle PR, Rommelaere J, Moehler M. Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires PML. World J Gastroenterol, 14(24): 3819-3828 [link]

Cite This Page:

World Journal of Gastroenterology. "New Therapeutic Option For Human Hepatocyte Cancer." ScienceDaily. ScienceDaily, 23 September 2008. <www.sciencedaily.com/releases/2008/09/080923104309.htm>.
World Journal of Gastroenterology. (2008, September 23). New Therapeutic Option For Human Hepatocyte Cancer. ScienceDaily. Retrieved July 28, 2015 from www.sciencedaily.com/releases/2008/09/080923104309.htm
World Journal of Gastroenterology. "New Therapeutic Option For Human Hepatocyte Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/09/080923104309.htm (accessed July 28, 2015).

Share This Page: